Gross Margin

Despite a slight revenue dip, Ultralife Corp. tripled its earnings per share. A look at how operational discipline and a record order book are charting its course.

Amidst declining North American sales, Under Armour is cutting products and chasing a premium identity. But can cost cuts and tariff refunds fuel a real comeback?

Interface posted stellar Q2 results, but a one-time $15.6M tariff refund inflated the numbers. The real story is the operational resilience of its strategy.

DouYu names a new CEO after the former chief's 'personal' exit, but a history of arrests and regulatory probes tells a deeper story of strategic survival.

Clarus Corp. stunned with a Q2 profit, but a $6.1M tariff refund clouds the picture. As one segment soars and another sinks, a strategic review looms.

Karat Packaging's profits surged 168% thanks to a massive one-time tariff refund. A deep dive reveals the real story lies in its strategic growth.

iRhythm's stellar Q2 results are just the start. A major acquisition and a new AI algorithm are set to reshape the cardiac monitoring landscape.

Arlo Technologies smashed expectations with record revenue, fueled by a masterful pivot to recurring services that now form the core of its business.

Beyond the mixed GAAP results, ICU Medical’s strong non-GAAP growth and raised guidance reveal a company thriving after a strategic pivot.

Resmed posts record revenue and boosts shareholder returns, but its strategic pivot and operational hurdles reveal a more complex story of medtech leadership.

NATR's Q2 results show a firm investing heavily in its digital future, with soaring e-commerce sales and subscription growth offsetting currency and China woes.

Stunning 120% revenue growth validates Senseonics' shift to in-house sales, but soaring costs and a widening net loss raise critical questions about its path to profitability.

Outset Medical's Q2 results reveal a pivotal moment: a major HCA deal and stronger margins point to a new phase of sustainable growth in the dialysis market.

Doximity's Q1 results reveal a company at a crossroads, sacrificing near-term profits for AI dominance. Engagement is soaring, but financials are strained.

Argentina's top cement firm posts a staggering profit jump, but a deeper analysis reveals operational struggles and a construction sector at a crossroads.

Amphastar beats Q2 estimates with new drug sales, but a deeper look reveals pricing pressure, rising costs, and a high-stakes bet on its pipeline.

A reported net loss obscures core growth at 10x Genomics. An acquisition, key partnerships, and a blockbuster product launch signal a decisive strategic pivot.

After Commerce.com's dismal Q2 results and stock plunge, AI-native rival Rezolve Ai declares its rejected merger proposal was the right path all along.

Where Food Comes From boosts profits via efficiency and new certifications like RaiseWell, offsetting beef market pressures and digital asset swings.

Delcath Systems posts strong revenue and profits, but the real story is its massive investment in expanding its unique liver therapy to fight breast cancer and more.